Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.85 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806072 | 1.00 | HRH3 (0.85) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL12677944 | 1.00 | HRH3 (0.85) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2806854 | 1.00 | HRH3 (0.85) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2812559 | 1.00 | HRH3 (0.85) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2806068 | 1.00 | HRH3 (0.85) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2806069 | 1.00 | HRH3 (0.85) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2811969 | 0.92 | HRH3 (1.00) | HRH3SLC6A4 | |
| SCHEMBL2805850 | 0.92 | HRH3 (1.00) | HRH3SLC6A4 | |
| SCHEMBL2805847 | 0.92 | HRH3 (1.00) | HRH3SLC6A4 | |
| SCHEMBL2805856 | 0.92 | HRH3 (1.00) | HRH3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | APODACA RICHARD (US) | 2012-12-20 | — | — | US | claimed |
| US-7754882-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-13 | — | — | US | claimed |
| US-20060293316-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | US | claimed |
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | APODACA RICHARD (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | APODACA RICHARD (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | APODACA RICHARD (US) | 2012-12-20 | — | — | US | disclosed |
| US-8273762-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-25 | — | — | US | disclosed |
| US-8273762-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-25 | — | — | US | disclosed |
| US-8273762-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-25 | — | — | US | disclosed |
| US-20100240648-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240648-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240648-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-23 | — | — | US | disclosed |
| US-7754882-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-13 | — | — | US | disclosed |
| US-7754882-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-13 | — | — | US | disclosed |
| US-7754882-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-13 | — | — | US | disclosed |
| EP-1893613-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006138604-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293316-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293316-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | HRH3 1/4885SLC6A4 15/4885SLC6A2 29/4885 |
| US-20100240648-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | HRH3 1/4885SLC6A4 15/4885SLC6A2 29/4885 |
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | HRH3 1/4885SLC6A4 15/4885SLC6A2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.